Investigators are conducting genetic studies of osteosarcoma to better understand the role that genetic variation plays in risk and patient outcomes, and to identify new genes or genomic regions that may be important in osteosarcoma pathogenesis. Our global collaborative effort includes researchers from The NCI Children’s Oncology Group (COG), Children’s Oncology Group study at the University of Minnesota and the Harvard School of Dental Medicine, U.S.A.; Universidad de Navarra, Pamplona, Spain; Institut Curie, France; Rizzoli Instituti, Italy; Royal Orthopaedic Hospital, UK; University of Toronto, Litwin Centre for Cancer Genetics, Canada; Instituto de Oncologia Pediátrica GRAACC/UNIFESP, Brazil; Ankara Oncology and Education Research Hospital, Turkey; Peter MacCallum Cancer Centre, Kinghorn Cancer Centre, and Garvan Institute of Medical Research, Australia. We estimate that approximately 2500 germline (blood or buccal cell) DNA samples will be genotyped at the NCI's Cancer Genomics Research (CGR) Laboratory and subsequently available for genome-wide association analyses. A team of biostatisticians has been assembled to create a common control set that will be derived from existing studies. Follow-up will include genotyping and sequence analyses of genomic regions associated with osteosarcoma.
For more information, contact Lisa Mirabello.